Hematologic disorders associated with hepatitis C virus infection and their management

Douglas T. Dieterich, Jerry L Spivak

Research output: Contribution to journalArticle

Abstract

More than 4 million people in the United States are infected with hepatitis C virus (HCV). During the next 20-30 years, the burden of HCV-related mortality and morbidity will likely double. To date, the most effective treatment for chronic HCV infection is the combination of either interferon (IFN)-α or pegylated IFN-α and ribavirin. For a sustained virologic response, treatment adherence and dose maintenance are essential. However, both IFN-α and ribavirin induce hematologic toxicity, such as anemia, neutropenia, and thrombocytopenia, which can compromise treatment adherence and dose maintenance and could, therefore, potentially influence outcomes. Although there are currently no approved treatments for hematologic complications of HCV therapy, studies have shown that hematopoietic growth factors can provide significant benefits. This review highlights the pharmacology, risks, and benefits of recombinant hematopoietic growth factor therapy in HCV-infected patients.

Original languageEnglish (US)
Pages (from-to)533-541
Number of pages9
JournalClinical Infectious Diseases
Volume37
Issue number4
DOIs
StatePublished - Aug 15 2003

Fingerprint

Virus Diseases
Hepacivirus
Interferons
Ribavirin
Intercellular Signaling Peptides and Proteins
Therapeutics
Maintenance
Chronic Hepatitis C
Neutropenia
Thrombocytopenia
Anemia
Pharmacology
Morbidity
Mortality

ASJC Scopus subject areas

  • Immunology

Cite this

Hematologic disorders associated with hepatitis C virus infection and their management. / Dieterich, Douglas T.; Spivak, Jerry L.

In: Clinical Infectious Diseases, Vol. 37, No. 4, 15.08.2003, p. 533-541.

Research output: Contribution to journalArticle

@article{5ec16107892048b2ab3f4771f96eae18,
title = "Hematologic disorders associated with hepatitis C virus infection and their management",
abstract = "More than 4 million people in the United States are infected with hepatitis C virus (HCV). During the next 20-30 years, the burden of HCV-related mortality and morbidity will likely double. To date, the most effective treatment for chronic HCV infection is the combination of either interferon (IFN)-α or pegylated IFN-α and ribavirin. For a sustained virologic response, treatment adherence and dose maintenance are essential. However, both IFN-α and ribavirin induce hematologic toxicity, such as anemia, neutropenia, and thrombocytopenia, which can compromise treatment adherence and dose maintenance and could, therefore, potentially influence outcomes. Although there are currently no approved treatments for hematologic complications of HCV therapy, studies have shown that hematopoietic growth factors can provide significant benefits. This review highlights the pharmacology, risks, and benefits of recombinant hematopoietic growth factor therapy in HCV-infected patients.",
author = "Dieterich, {Douglas T.} and Spivak, {Jerry L}",
year = "2003",
month = "8",
day = "15",
doi = "10.1086/376971",
language = "English (US)",
volume = "37",
pages = "533--541",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Hematologic disorders associated with hepatitis C virus infection and their management

AU - Dieterich, Douglas T.

AU - Spivak, Jerry L

PY - 2003/8/15

Y1 - 2003/8/15

N2 - More than 4 million people in the United States are infected with hepatitis C virus (HCV). During the next 20-30 years, the burden of HCV-related mortality and morbidity will likely double. To date, the most effective treatment for chronic HCV infection is the combination of either interferon (IFN)-α or pegylated IFN-α and ribavirin. For a sustained virologic response, treatment adherence and dose maintenance are essential. However, both IFN-α and ribavirin induce hematologic toxicity, such as anemia, neutropenia, and thrombocytopenia, which can compromise treatment adherence and dose maintenance and could, therefore, potentially influence outcomes. Although there are currently no approved treatments for hematologic complications of HCV therapy, studies have shown that hematopoietic growth factors can provide significant benefits. This review highlights the pharmacology, risks, and benefits of recombinant hematopoietic growth factor therapy in HCV-infected patients.

AB - More than 4 million people in the United States are infected with hepatitis C virus (HCV). During the next 20-30 years, the burden of HCV-related mortality and morbidity will likely double. To date, the most effective treatment for chronic HCV infection is the combination of either interferon (IFN)-α or pegylated IFN-α and ribavirin. For a sustained virologic response, treatment adherence and dose maintenance are essential. However, both IFN-α and ribavirin induce hematologic toxicity, such as anemia, neutropenia, and thrombocytopenia, which can compromise treatment adherence and dose maintenance and could, therefore, potentially influence outcomes. Although there are currently no approved treatments for hematologic complications of HCV therapy, studies have shown that hematopoietic growth factors can provide significant benefits. This review highlights the pharmacology, risks, and benefits of recombinant hematopoietic growth factor therapy in HCV-infected patients.

UR - http://www.scopus.com/inward/record.url?scp=0042442463&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042442463&partnerID=8YFLogxK

U2 - 10.1086/376971

DO - 10.1086/376971

M3 - Article

C2 - 12905138

AN - SCOPUS:0042442463

VL - 37

SP - 533

EP - 541

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 4

ER -